特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
833182

新型出生前診断 (NIPT) に重点を置いたリキッドバイオプシー:世界市場の予測 (~2023年)

Liquid Biopsy with Emphasis on NIPT: Global Markets to 2023

出版日: | 発行: BCC Research | ページ情報: 英文 359 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
新型出生前診断 (NIPT) に重点を置いたリキッドバイオプシー:世界市場の予測 (~2023年)
出版日: 2019年04月26日
発行: BCC Research
ページ情報: 英文 359 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界におけるリキッドバイオプシー市場は、2018年の23億米ドルから、2023年までに61億米ドルへ拡大すると予測され、この間は21.1%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界のリキッドバイオプシー市場について、特に新型出生前診断 (NIPT) に重点を置いて調査しており、世界市場の概要、世界市場の動向分析と予測、市場の促進要因・抑制要因のほか、規制環境、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場・技術背景

  • リキッドバイオプシーの概要
  • リキッドバイオプシー vs. 従来型バイオプシー
  • リキッドバイオプシーのバイオマーカー
  • 従来型バイオプシーを用いたリキッドバイオプシーの比較
  • 成長促進要因
  • 主な動向
  • リキッドバイオプシーにおける主な発展

第4章 リキッドバイオプシーのイニシアチブ

  • Blood Profiling Atlas
  • Cambridge Single Cell Analysis Core Facility
  • Cancer-ID
  • CTCTrap Consortium
  • Early Cancer Detection Consortium
  • Hematologic Oncology Consortium
  • National Center for Single-Cell Biology
  • Precancer Genome Atlas
  • Precision Medicine Initiative
  • Single Cell Analysis Program
  • TopMed
  • Worldwide Innovative Networking (WIN) Consortium
  • 癌検出向けNIPT

第5章 リキッドバイオプシーの用途

  • イントロダクション
  • 癌の用途
  • リプロダクティブヘルス用途
  • 移植診断用途

第6章 リキッドバイオプシーの2次産業

  • イントロダクション
  • 先進シーケンシング装置産業
  • NGS装置産業
  • 第3世代シーケンシング産業
  • ドロップレットデジタルPCR産業
  • ターゲットエンリッチメント・増幅産業
  • シングルセルDNAポリメラーゼ産業
  • NGS臨床インフォマティクス産業
  • 試験サービス産業
  • NIPT産業
  • 胎児細胞NIPT産業
  • CTCキャプチャー・検出産業
  • リキッドバイオプシー産業
  • DTC遺伝子検査産業

第7章 リキッドバイオプシー産業

  • 成長促進要因
  • リキッドバイオプシー市場:用途別
  • リキッドバイオプシー市場:バイオマーカータイプ別
  • リキッドバイオプシー市場:分析プラットフォーム別
  • リキッドバイオプシー市場:分析目的別
  • 地域市場

第8章 市場分析:適応症別 - 癌および移植

  • 癌市場
  • 移植市場

第9章 NIPT産業

第10章 リキッドバイオプシー:NIPTのエンドユーザー

  • 疾病領域別

第11章 特許レビュー/新規開発

  • 特許レビュー:年度別
  • 循環腫瘍細胞の特許
  • リキッドバイオプシーおよびシーケンシング関連特許の問題

第12章 市場機会の分析

  • 市場シェア分析
  • PEST分析

第13章 競合情勢

  • M&A
  • 新製品発売
  • 合意、協力および提携
  • パイプライン分析

第14章 企業プロファイル

BBC Researchについて

図表

List of Tables

  • Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023
    • Table 1: Liquid Biopsy Sample Types
    • Table 2: Liquid Biopsy Biomarker Classes
    • Table 3: Clinical Implications of CTCs
    • Table 4: Key Applications of Circulating Tumor DNA (ctDNA)
    • Table 5: Comparison between Applications of ctDNA, CTCs and Exosomes
    • Table 6: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 7: Genomics-Based Oncology Workflow
    • Table 8: Unique Challenges of CTC Capture and Analysis
    • Table 9: CTC Workflow
    • Table 10: Cell Differentiators
    • Table 11: Cell Isolation Technologies
    • Table 12: CTC-Isolating Markers
    • Table 13: CTC Sample Preparation Technologies
    • Table 14: Single-Cell Analysis Technologies
    • Table 15: Difference between Liquid Biopsy and Traditional Biopsy
    • Table 16: Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers
    • Table 17: Main Risks for Needle-Based Tissue Biopsies
    • Table 18: Factors in Tissue Biopsy
    • Table 19: Prenatal Invasive Testing Technologies
    • Table 20: Invasive versus Noninvasive Prenatal Technologies
    • Table 21: Growth Driving Forces
    • Table 22: Key Trends in Liquid Biopsy Market
    • Table 23: Key Liquid Biopsy Research and Development Programs
    • Table 24: Source of Foreign Biomarkers for Liquid Biopsy Applications
    • Table 25: Personalized Medicine Driven by Cancer Common Genetic Mutations
    • Table 26: Cancer Liquid Biopsy Biomarker Clinical Status
    • Table 27: Cancer Liquid Biopsy Market Segments
    • Table 28: Reproductive Health Screening Application
    • Table 29: Ethical Issues Associated with NIPT
    • Table 30: Transplant Diagnostics Application
    • Table 31: Key Segments within the Liquid Biopsy Industry
    • Table 32: Advanced Sequencing Industry Company Positioning
    • Table 33: End-to-End Sequencing Approaches
    • Table 34: Next-Generation Sequencing Instrument Companies
    • Table 35: NGS Instruments
    • Table 36: Benchtop and Handheld Sequencer Platforms
    • Table 37: 3GS Industry, by Tier Status
    • Table 38: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 39: Droplet Digital PCR Industry
    • Table 40: Target Enrichment Industry
    • Table 41: Single-Cell DNA Polymerase Industry
    • Table 42: Next-Generation Sequencing Clinical Informatics Company Positioning
    • Table 43: Selected NGS Clinical Testing Laboratories
    • Table 44: NIPT Industry
    • Table 45: Estimated Market Share for NIPT, 2018
    • Table 46: German NGS-Based Noninvasive Prenatal Diagnostic Companies, 2017
    • Table 47: NIPT Test Licensing, by Country
    • Table 48: Fetal Cell NIPT Industry
    • Table 49: CTC Capture and Detection Industry
    • Table 50: Liquid Biopsy Industry by Company Focus
    • Table 51: Example of NGS-Based Liquid Biopsy Market Differentiation
    • Table 52: Key Competitors in the Direct-to-Consumer Genetic Testing Industry
    • Table 53: Liquid Biopsy Key Growth Driving Forces
    • Table 54: Global Liquid Biopsy Market, by Application, Through 2023
    • Table 55: Global Liquid Biopsy Market, by Biomarker Type, Through 2023
    • Table 56: FDA-Approved or CE-Marked Tests with Epigenetic Component
    • Table 57: Global Liquid Biopsy Market, by Analysis Platform, Through 2023
    • Table 58: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
    • Table 59: Global Liquid Biopsy Market, by Region, Through 2023
    • Table 60: Limitations of Solid Biopsy in Cancer Applications
    • Table 61: Low-Frequency Mutation Detection
    • Table 62: Global Liquid Biopsy Cancer Market, by Indication, Through 2023
    • Table 63: Five-Year Survival Rate for Ovarian Cancer
    • Table 64: National Institutes of Health Liquid Biopsy Early Detection Initiative
    • Table 65: Molecular Thyroid Nodule Classifier Test Company Positioning
    • Table 66: Global Liquid Biopsy Cancer Market, by Analysis Purpose, Through 2023
    • Table 67: MRI and Liquid Biopsy Methods
    • Table 68: Early Detection Tissue of Origin Approaches
    • Table 69: Global Liquid Biopsy Cancer Market, by Biomarker Class, Through 2023
    • Table 70: Global Liquid Biopsy Cancer Market, by Analysis Method, Through 2023
    • Table 71: Global Breast Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 72: Global Colorectal Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 73: Global Hematological Cancer Market, by Analysis Method, Through 2023
    • Table 74: Global Lung Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 75: Global Pan-Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
    • Table 76: Global Cancer Liquid Biopsy Market, by Region, Through 2023
    • Table 77: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2023
    • Table 78: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2023
    • Table 79: Transplant Procedures Performed in the U.S., 2016-Sept. 30, 2018
    • Table 80: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2023
    • Table 81: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2023
    • Table 82: Global Transplant Liquid Biopsy Market, by Region, Through 2023
    • Table 83: NIPT Test Prices Across the Globe, 2017
    • Table 84: Global NIPT Market, by Analysis Purpose, Through 2023
    • Table 85: Global NIPT Market, by Risk Type, Through 2023
    • Table 86: Global NIPT Market, by Biomarker Class, Through 2023
    • Table 87: Global NIPT Market, by Analysis Method, Through 2023
    • Table 88: NGS NIPT Industry
    • Table 89: Number of Tests and Market for NIPT, by Region and Company, 2015
    • Table 90: Germany NGS-Based Noninvasive Prenatal Diagnostic Companies
    • Table 91: Global NIPT Market, by Method, Through 2023
    • Table 92: NIPTs Offered by Various Companies
    • Table 93: Positive Predictive Values for High- and Average-Risk Cohorts
    • Table 94: Comparison with Other NIPTs That are Based on Counting Technologies
    • Table 95: Global Iona Test Market, by Country/Region, 2016 and 2017
    • Table 96: informaSeq Tests
    • Table 97: informaSeq Test Performance in the Most Common Chromosomal Aneuploidies
    • Table 98: informaSeq Test Performance in the Most Common Sex Chromosomes
    • Table 99: VisibiliT Test Performance
    • Table 100: Global NIPT Market, by Region, Through 2023
    • Table 101: North American NIPT Market, by Country, Through 2023
    • Table 102: Commercial Landscape of Noninvasive Prenatal Testing for Fetal Aneuploidy in the U.S.
    • Table 103: U.S. Patents and Applications for Institutions Commercializing Noninvasive Prenatal Tests, 2012
    • Table 104: European NIPT Market, by Country, Through 2023
    • Table 105: Asia-Pacific NIPT Market, by Country, Through 2023
    • Table 106: NIPT Technology Transfers, by Country
    • Table 107: Patent Review of NIPT, by Year, 2010-2018
    • Table 108: CTC-Related Patents, by Region, 2007-2019*
    • Table 109: Cell-Free DNA-Related Patents, by Region, 2007-2017
    • Table 110: Status of Liquid Biopsy- and Sequencing-Related Patent Disputes
    • Table 111: Mergers and Acquisitions of Key Players, 2016-2018
    • Table 112: New Products Launched by Key Players of NGS-NIPT Industry, 2017 and 2018
    • Table 113: Agreements, Collaborations and Partnerships among Liquid Biopsy-NIPT Key Players, 2017 and 2018
    • Table 114: Pipeline Analysis of Liquid Biopsy Industry, 2017 and 2018
    • Table 115: 10x Genomics: Products and Services
    • Table 116: Agilent Technologies: Financials, 2016-2017
    • Table 117: Agilent Technologies: Products and Services
    • Table 118: Berry Genomics: Products and Services
    • Table 119: BGI: Products and Services
    • Table 120: LifeCodexx: Products and Services
    • Table 121: Illumina: Financials, 2016-2017
    • Table 122: Illumina: Products and Services
    • Table 123: LabCorp: Financials, 2016-2017
    • Table 124: LabCorp: Products and Services
    • Table 125: Natera: Financials, 2016-2017
    • Table 126: Natera: Products and Services
    • Table 127: Oxford Nanopore Technologies: Products and Services
    • Table 128: Pacific Biosciences: Financials, 2016-2017
    • Table 129: PacBio: Products and Services
    • Table 130: PDx: Products and Services
    • Table 131: QIAGEN: Financials, 2016-2017
    • Table 132: QIAGEN: Products and Services
    • Table 133: Roche Diagnostics: Division Sales, 2016-2017
    • Table 134: Roche Diagnostics: Products and Services
    • Table 135: Thermo Fisher: Financials, 2016-2017
    • Table 136: Thermo Fisher: Products and Services

List of Figures

  • Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023
    • Figure 1: Timeline of Liquid Biopsy Development
    • Figure 2: Molecular Applications of Biomarkers as Liquid Biopsy for Personalized Medicine
    • Figure 3: How Cancer Genomics Drives Liquid Biopsy
    • Figure 4: Clinical Applications of Liquid Biopsy for Precision Medicine
    • Figure 5: NIPT Using Massively Parallel Sequencing (MPS)
    • Figure 6: Global NIPT Market, by Risk Type, 2017-2023
    • Figure 7: Clinical Performance of NIFTY Test
    • Figure 8: Clinical Performance of Harmony Test
    • Figure 9: Clinical Performance of Panorama Test
    • Figure 10: North American NIPT Market, 2017-2023
    • Figure 11: European NIPT Market, 2017-2023
    • Figure 12: European NIPT Market Share, 2017
    • Figure 13: Mean Maternal Age in Five EU Countries, 2016
    • Figure 14: Total Number of Pregnancies and NIPT Procedures in Five EU Countries, 2016
    • Figure 15: Asia-Pacific NIPT Market, 2017-2023
    • Figure 16: RoW NIPT Market, 2017-2023
    • Figure 17: Prevalence of Down Syndrome by Mother's Age
    • Figure 18: Global NIPT Market Share, by Key Players, 2018
    • Figure 19: Thermo Fisher Scientific: Market Share, by Business Segments, 2018 (Q1)
目次
Product Code: HLC235A

Report Highlights:

The global liquid biopsy market should grow from $2.3 billion in 2018 to $6.1 billion by 2023, at a compound annual growth rate (CAGR) of 21.1% for the period of 2018-2023.

Non-cancer liquid biopsy market should grow from $1.9 billion in 2018 to $3.7 billion by 2023 at a CAGR of 14.1% through 2023.

Cancer liquid biopsy market should grow from $411.7 million in 2018 to $2.4 billion by 2023 at a CAGR of 41.7% through 2023.

Report Scope:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, NIPT methods, patents for both liquid biopsy and NIPT, and company profiles. The market sizes for liquid biopsy diagnostics with emphasis on NIPT are given for the years 2017, 2018 (estimated) and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Market-driving forces are also discussed.

In addition to this, the report examines the markets by NIPT methods, high-risk and low-risk pregnancies and geography. The end-user segment of this market is based on disease area and healthcare setting. Disease areas include trisomy 21, 18 and 13 and Turner syndrome (a sex chromosome aneuploidy). Healthcare settings include diagnostic laboratories and hospitals. Market dynamics such as drivers and restraints for the NIPT market are also discussed.

The structure of several important industry subsectors was reviewed. The industry subsectors that are analyzed include next-generation sequencing (NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and others), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World). Similarly, the market size of non-cancer applications of liquid biopsy, NIPT, is analyzed based on risk-type, analysis purpose, biomarker class, analysis method, NIPT methods, high- and low-risk pregnancies, and geography.

Market data cover the years 2017, 2018 (estimated) and 2023 (forecasted).

More than 165 companies in the liquid biopsy industry are profiled in this report. Nearly 18 companies in the NIPT market have been profiled in detail.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 until December 2018, including key alliance trends.

Report Includes:

  • 45 data tables and 94 additional tables
  • An overview of liquid biopsy and non-invasive prenatal tests (NIPT) market
  • Analyses of global market trends with data from 2017, 2018 and projections of compound annual growth rates (CAGRs) through 2023
  • Country specific data and analysis for China, Japan, India, South Korea, UK, Germany, France, Italy, Spain and USA
  • Comparative study of liquid biopsy with conventional biopsy and coverage of their respective biomarkers
  • Snapshot of key liquid biopsy research and development programs
  • Information on NIPT available in market such as NIFTY, Verifi prenatal test, Harmony prenatal test, Panorama, MaterniT21 and IONA test
  • Description of chromosomal diseases where NIPT plays a vital role in detection and screening i.e. Down's Syndrome, Edwards Syndrome (Trisomy 18), Patau syndrome (Trisomy 13) and Turner syndrome
  • Comprehensive company profiles of major players, including Agilent Technologies, Illumina, Natera, Oxford Nanopore, QIAGEN, and Thermo Fisher

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of the Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Liquid Biopsy Overview
  • Liquid Biopsy versus Traditional Biopsy
  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Noninvasive Prenatal Testing
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Prenatal Testing
  • Growth Driving Forces
  • Key Trends
  • Key Developments in Liquid Biopsy

Chapter 4: Liquid Biopsy Initiatives

  • Blood Profiling Atlas
  • Cambridge Single Cell Analysis Core Facility
  • Cancer-ID
  • CTCTrap Consortium
  • Early Cancer Detection Consortium
  • Hematologic Oncology Consortium
  • National Center for Single-Cell Biology
  • Precancer Genome Atlas
  • Precision Medicine Initiative
  • Single Cell Analysis Program
  • TopMed
  • Worldwide Innovative Networking (WIN) Consortium
  • NIPT for Cancer Detection
  • Research Studies on NIPT for Cancer Detection

Chapter 5: Liquid Biopsy Applications

  • Introduction
  • Cancer Applications
  • Precision Medicine
  • Cancer Biomarker Status
  • Cancer Market Segments
  • Reproductive Health Applications
  • Transplant Diagnostics Applications

Chapter 6: Liquid Biopsy Subindustries

  • Introduction
  • Advanced Sequencing Instruments Industry
  • NGS Instrument Industry
  • MiSeq
  • NextSeq
  • MiniSeq
  • ISeq 100
  • Ion Torrent
  • PromethION
  • MinION
  • GridION X5
  • Third-Generation Sequencing Industry
  • Droplet Digital PCR Industry
  • Target Enrichment and Amplification Industry
  • Single-Cell DNA Polymerase Industry
  • NGS Clinical Informatics Industry
  • Testing Services Industry
  • Noninvasive Prenatal Testing Industry
  • Fetal Cell NIPT Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Industry
  • Direct-to-Consumer Genetic Testing Industry

Chapter 7: Liquid Biopsy Industry

  • Growth Driving Forces
  • Liquid Biopsy Market by Application
  • Liquid Biopsy Market by Biomarker Type
  • Liquid Biopsy Market by Analysis Platform
  • Liquid Biopsy Market by Analysis Purpose
  • Geographical Market

Chapter 8: Market Breakdown by Indication-Cancer and Transplant

  • Cancer Markets
  • Cancer Market by Indication
  • Cancer Market by Analysis Purpose
  • Cancer Market by Biomarker Class
  • Cancer Market by Analysis Method
  • Breast Cancer Market
  • Colorectal Cancer Market
  • Hematological Cancer Market
  • Lung Cancer Market
  • Pan-Cancer Market
  • Geographical Market
  • Transplant Markets
  • Geographical Market

Chapter 9: NIPT Industry

  • NIPT-Introduction and Technology Overview
  • Other Conventional Prenatal Testing Methods
  • Advantages of NIPT
  • Positive Predictive Value
  • Implementation of NIPT Process
  • In-house Testing
  • As a Service
  • Factors Driving NIPT Market
  • Average Risk NIPT
  • Favorable Reimbursement
  • New Advances in Genomic Technologies
  • Preference for Noninvasive Techniques over Invasive Methods
  • Patient Counseling and Awareness
  • Increasing Collaborations with Local Entities
  • Increasing Mean Maternal Age
  • Restraints
  • Legal and Regulatory Issues
  • Access to Advancing Technologies
  • Current Market Scenario
  • Cost of NIPT
  • NGS-Based NIPT
  • NGS Sequencers for NIPT
  • VeriSeq NIPT Solution
  • MiSeqDx
  • NextSeq 550x
  • NextSeq 550AR
  • Noninvasive Prenatal Tests Available in Market
  • NIFTY
  • Verifi Prenatal Test
  • Harmony Prenatal Test
  • Panorama
  • MaterniT21
  • IONA Test
  • Iona Test Workflow
  • Bambni Test
  • informaSeq
  • Prena Test
  • VisibiliT
  • VERACITY
  • Geographical Market
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 10: Liquid Biopsy-NIPT End Users

  • By Disease Area
  • Down Syndrome (Trisomy 21)
  • Edwards Syndrome (Trisomy 18)
  • Patau Syndrome (Trisomy 13)
  • Turner Syndrome
  • Others
  • By Healthcare Setting
  • Diagnostic Laboratories
  • Hospitals

Chapter 11: Patent Review/ New Developments

  • Patent Review by Year
  • Circulating Tumor Cell Patents
  • Cell-Free DNA Patents
  • Liquid Biopsy- and Sequencing-Related Patent Issues

Chapter 12: Analysis of Market Opportunities

  • Market Share Analysis
  • PEST Analysis
  • Political
  • Economical
  • Social
  • Technological

Chapter 13: Competitive Landscape

  • Mergers and Acquisitions
  • New Product Launches
  • Agreements, Collaborations and Partnerships
  • Pipeline Analysis

Chapter 14: Company Profiles

  • Key Players in NIPT Industry
  • 10X GENOMICS
  • AGILENT TECHNOLOGIES INC.
  • BERRY GENOMICS
  • BGI (BEIJING GENOMICS INSTITUTE)
  • EUROFINS GATC BIOTECH
  • EUROFINS GATC-LIFECODEXX AG
  • ILLUMINA INC.
  • KNOME INC./TUTE GENOMICS/PIERIAN DX
  • LABCORP
  • LABCORP-SEQUENOM LABORATORIES
  • NATERA INC.
  • NIPD GENETICS
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA
  • PIERIANDX INC.
  • PERKINELMER INC.
  • QIAGEN N.V.
  • ROCHE HOLDING AG
  • THERMO FISHER SCIENTIFIC INC.
  • Players in the Liquid Biopsy Industry
  • 3D SIGNATURES
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ALCEDIAG
  • AMBRY GENETICS
  • ANGLE PLC
  • APOCELL INC.
  • ARUP LABORATORIES
  • ASURAGEN INC.
  • ATRECA INC.
  • AVIVA BIOSCIENCES
  • BAYLOR MIRACA GENETICS LABORATORIES INC.
  • BECTON, DICKINSON AND CO.
  • BELLWETHER BIO INC.
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFLUIDICA INC.
  • BIOGAZELLE
  • BIOMARX INC.
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE LTD.
  • BIOVENDOR-LABORATORNI MEDICINA A.S.
  • BOREAL GENOMICS
  • CANCER GENETICS
  • CEGAT GMBH
  • CELLMAX LIFE
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CIRCULOMICS INC.
  • CLINOMICS CO. LTD.
  • CODIAK BIOSCIENCES
  • COLOR GENOMICS
  • COOPERSURGICAL INC.
  • CORIELL LIFE SCIENCES INC.
  • CYNVENIO BIOSYSTEMS INC.
  • CYTOTRACK APS
  • DANAHER CORP. /HACH CO.
  • DIACARTA INC.
  • DIAGNOLOGIX LLC
  • DIAGNOMICS
  • DIPLOID
  • DNA ELECTRONICS LTD.
  • DNALYTICS
  • DNANEXUS INC.
  • EDICO GENOME
  • ENVISION GENOMICS
  • EPIC SCIENCES
  • EXACT SCIENCES CORP.
  • EXOSOME DIAGNOSTICS INC.
  • FABRIC GENOMICS INC.
  • FLUXION BIOSCIENCES INC.
  • FOUNDATION MEDICINE INC.
  • FREENOME INC.
  • GENAPSYS INC.
  • GENEDX INC.
  • GENOMATIX SOFTWARE GMBH
  • GENOMIC HEALTH INC.
  • GENOMONCOLOGY
  • GENOSPACE
  • GIGAGEN INC.
  • GOOD START GENETICS INC.
  • GOLDEN HELIX
  • GRAIL
  • GUARDANT HEALTH INC.
  • HELITEC
  • HELIX OPCO LLC
  • HTG MOLECULAR DIAGNOSTICS INC.
  • HUMAN LONGEVITY INC.
  • INEX INNOVATIONS EXCHANGE PTE LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC
  • INVITAE
  • INVIVOSCRIBE INC.
  • IREPERTOIRE INC.
  • KELLBENX INC.
  • LABORATORY CORP. OF AMERICA INC.
  • MDNA LIFE SCIENCES INC.
  • MDX HEALTH INC.
  • MEDGENOME LABS PVT. LTD.
  • MENARINI SILICON BIOSYSTEMS
  • MERCK KGAA
  • MOLECULAR HEALTH GMBH
  • MYRIAD GENETICS INC.
  • NAMOCELL INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NEOGENOMICS INC.
  • NEW ENGLAND BIOLABS
  • NEW ONCOLOGY GMBH
  • N-OF-ONE INC.
  • NOVOGENE CORP.
  • NUGEN TECHNOLOGIES INC.
  • NX PRENATAL INC.
  • ONCOCYTE CORP.
  • ONCODNA SA
  • PANGAEA ONCOLOGY
  • PARADIGM DIAGNOSTICS INC.
  • PARSEQ LAB S.R.O.
  • PATHWAY GENOMICS CORP.
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PORTABLE GENOMICS LLC
  • PREDICINE INC.
  • PRENETICS
  • PROVISTA DIAGNOSTICS INC.
  • QUANTAPORE INC.
  • QUANTUM BIOSYSTEMS INC.
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECELLS SAS
  • RARECYTE INC.
  • REAL TIME GENOMICS INC.
  • RESOLUTION BIOSCIENCE INC.
  • SCREENCELL
  • SENGENICS INTERNATIONAL PTE LTD.
  • SEQUENCING.COM
  • SEVEN BRIDGES GENOMICS INC.
  • SINGLERA GENOMICS
  • SOPHIA GENETICS
  • SPERA MEDICAL
  • SPHERE FLUIDICS LTD.
  • STATION X INC.
  • STILLA TECHNOLOGIES
  • STRAND LIFE SCIENCES PVT. LTD.
  • STRATEC BIOMEDICAL AG
  • STRATOS GENOMICS INC.
  • SYAPSE
  • SYGNIS AG
  • SYSMEX INOSTICS GMBH
  • TAI DIAGNOSTICS INC.
  • TAKARA BIO INC.
  • THORNE DIAGNOSTICS INC.
  • TROVAGENE INC.
  • TRANSGENOMIC INC.
  • TWINSTRAND BIOSCIENCES
  • TWO PORE GUYS INC.
  • UBIQUITY GENOMICS INC.
  • VELA DIAGNOSTICS
  • VOLITIONRX
  • XCELL BIOSCIENCES INC.
  • YIKON GENOMICS CO. LTD.
  • YOURGENE HEALTH PLC
  • ZS GENETICS INC.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.